Home
ELAB
ELAB News

Latest Elevai Labs Inc. (ELAB) News on September 9, 2025

MT Newswires

3 months ago

PMGC Signs LOI to Acquire CNC Machining Firm; Shares Rise

PMGC Holdings Inc. Signs Non-Binding LOI to Acquire CNC Aerospace Manufacturer Generating $4.5 Million in Annual Revenue

GlobeNewswire

3 months ago

PMGC Holdings Inc. Signs Non-Binding LOI to Acquire CNC Aerospace Manufacturer Generating $4.5 Million in Annual Revenue

PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies

GlobeNewswire

3 months ago

PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies

Northstrive announces initiation of Phase II of AI Development Program

TipRanks

3 months ago

Northstrive announces initiation of Phase II of AI Development Program

Northstrive Biosciences Announces Initiation of Phase II of Collaboration to Develop AI Powered Therapies for Obesity and Cardiometabolic Diseases

GlobeNewswire

3 months ago

Northstrive Biosciences Announces Initiation of Phase II of Collaboration to Develop AI Powered Therapies for Obesity and Cardiometabolic Diseases

PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based AS9100D & ISO 9001:2015 Certified CNC Machine Shop Serving Aerospace, Defense, and Industrial Markets for over 35 years

GlobeNewswire

3 months ago

PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based AS9100D & ISO 9001:2015 Certified CNC Machine Shop Serving Aerospace, Defense, and Industrial Markets for over 35 years

MT Newswires

3 months ago

PMGC Plans to Acquire US-based Electronics Manufacturing Firm; Shares Rise

PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Electronics Manufacturing Company

GlobeNewswire

3 months ago

PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Electronics Manufacturing Company

NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia

GlobeNewswire

4 months ago

NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia

PMGC Holdings Inc. Announces Filing of Quarterly Report on Form 10-Q

GlobeNewswire

4 months ago

PMGC Holdings Inc. Announces Filing of Quarterly Report on Form 10-Q

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

GlobeNewswire

4 months ago

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

Northstrive Biosciences Signs Binding Term Sheet with Modulant Biosciences for Exclusive Global Animal Health Licensing of EL-22

GlobeNewswire

4 months ago

Northstrive Biosciences Signs Binding Term Sheet with Modulant Biosciences for Exclusive Global Animal Health Licensing of EL-22

RESEND - Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health

GlobeNewswire

4 months ago

RESEND - Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health

Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health

GlobeNewswire

4 months ago

Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health

Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial

GlobeNewswire

4 months ago

Northstrive Biosciences Co-Founder Featured on Bear Bull Traders Following Announcement of Positive FDA Response Supporting Submission of IND for EL-22 Phase 2 Clinical Trial

Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment

GlobeNewswire

5 months ago

Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment

MT Newswires

5 months ago

PMGC Signs Letter of Intent to Purchase Custom IT Packaging Firm; Shares Fall

PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company

GlobeNewswire

5 months ago

PMGC Holdings Inc. Signs Letter of Intent to Acquire Profitable U.S.-Based Custom IT Packaging Company

Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases

GlobeNewswire

5 months ago

Northstrive Biosciences Signs Partnership with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases

PMGC Holdings Inc. Announces Filing of Annual Report on Form 10-K

GlobeNewswire

5 months ago

PMGC Holdings Inc. Announces Filing of Annual Report on Form 10-K

NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market

GlobeNewswire

5 months ago

NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market

Univest Securities, LLC Announces Closing of $1.48 Million Registered Direct Offering for its Client PMGC Holdings Inc. (NASDAQ: ELAB)

GlobeNewswire

5 months ago

Univest Securities, LLC Announces Closing of $1.48 Million Registered Direct Offering for its Client PMGC Holdings Inc. (NASDAQ: ELAB)

PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules

GlobeNewswire

6 months ago

PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules

PMGC Holdings Announces Share Repurchases from Existing Shareholders

GlobeNewswire

6 months ago

PMGC Holdings Announces Share Repurchases from Existing Shareholders

Is PMGC Holdings (NASDAQ:ELAB) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

6 months ago

Is PMGC Holdings (NASDAQ:ELAB) In A Good Position To Deliver On Growth Plans?

Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

GlobeNewswire

6 months ago

Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

MT Newswires

6 months ago

Top Midday Decliners

MT Newswires

6 months ago

PMGC to Implement 1-for-7 Reverse Stock Split; Shares Fall

PMGC Holdings Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance

GlobeNewswire

6 months ago

PMGC Holdings Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance

PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

GlobeNewswire

6 months ago

PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

PMGC Holdings Highlights Strong Capital Position: No Debt, Fully Funded, and Warrants Priced Above Market

GlobeNewswire

6 months ago

PMGC Holdings Highlights Strong Capital Position: No Debt, Fully Funded, and Warrants Priced Above Market

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 Receptor Agonists

GlobeNewswire

7 months ago

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 Receptor Agonists

Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1

GlobeNewswire

7 months ago

Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1

PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fire Prevention Technology Companies

GlobeNewswire

7 months ago

PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fire Prevention Technology Companies

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

GlobeNewswire

7 months ago

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

PMGC Holdings Inc. Announces $1.9 Million in Gross Proceeds from Warrant Inducement with Institutional Investors

GlobeNewswire

7 months ago

PMGC Holdings Inc. Announces $1.9 Million in Gross Proceeds from Warrant Inducement with Institutional Investors

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium

GlobeNewswire

8 months ago

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium

PMGC Holdings Inc. Announces Closing of Elevai Skincare Divestiture

GlobeNewswire

8 months ago

PMGC Holdings Inc. Announces Closing of Elevai Skincare Divestiture

PMGC Holdings Inc. Announces Name Change of Wholly Owned Subsidiaries

GlobeNewswire

8 months ago

PMGC Holdings Inc. Announces Name Change of Wholly Owned Subsidiaries

PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy

GlobeNewswire

8 months ago

PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy

Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products

GlobeNewswire

8 months ago

Carmell Announces Execution of Definitive Agreement to Acquire Elevai Skincare, a leader in Physician Dispensed Exosome Skin and Hair Care Products

Elevai Labs plans name change to PMGC Holdings, redomicile to Nevada

TipRanks

9 months ago

Elevai Labs plans name change to PMGC Holdings, redomicile to Nevada

Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada

GlobeNewswire

9 months ago

Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada

Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada

GlobeNewswire

9 months ago

Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation

GlobeNewswire

9 months ago

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation

Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market

GlobeNewswire

9 months ago

Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market

Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division

GlobeNewswire

9 months ago

Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division

Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance

GlobeNewswire

10 months ago

Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance

Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess

GlobeNewswire

10 months ago

Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess

Elevai Labs Third Quarter 2024 Earnings: US$0.068 loss per share (vs US$0.078 loss in 3Q 2023)

Simply Wall St.

10 months ago

Elevai Labs Third Quarter 2024 Earnings: US$0.068 loss per share (vs US$0.078 loss in 3Q 2023)

CORRECTION - Elevai Labs Inc.

GlobeNewswire

10 months ago

CORRECTION - Elevai Labs Inc.

Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update

GlobeNewswire

10 months ago

Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

GlobeNewswire

10 months ago

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity

GlobeNewswire

a year ago

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity

GlobeNewswire

a year ago

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity

Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock

GlobeNewswire

a year ago

Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock

MT Newswires

a year ago

Sector Update: Health Care Stocks Fall Late Afternoon

REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

GlobeNewswire

a year ago

REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

MT Newswires

a year ago

Top Midday Gainers

MT Newswires

a year ago

Elevai Labs Unit Seeks Patents for Lead Drug Candidate to Treat Muscle Loss in Obese Patients

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

GlobeNewswire

a year ago

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device

GlobeNewswire

a year ago

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device

Altium Capital Management LP Acquires New Stake in Elevai Labs Inc

GuruFocus.com

a year ago

Altium Capital Management LP Acquires New Stake in Elevai Labs Inc

MT Newswires

a year ago

Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday

MT Newswires

a year ago

Elevai Labs Closes $8 Million Securities Offering; Shares Rise After Hours

Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB)

GlobeNewswire

a year ago

Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB)

MT Newswires

a year ago

Top Midday Decliners

MT Newswires

a year ago

Elevai Labs Prices $8 Million Public Offering; Shares Fall Pre-Bell

Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering

GlobeNewswire

a year ago

Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications

GlobeNewswire

a year ago

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications

MT Newswires

a year ago

Elevai Labs Says Study of Exosome Technology Shows Reversal of Hair Thinning; Shares Rise Pre-Bell

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology

GlobeNewswire

a year ago

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology

MT Newswires

a year ago

Elevai Labs, Yuva Biosciences File 2 Hair Treatment Patents

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™

GlobeNewswire

a year ago

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™

MT Newswires

a year ago

Elevai Labs Reports Skin Improvement in Exosome Study -- Shares Jump Pre-Bell

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum

GlobeNewswire

a year ago

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum

Elevai Labs Second Quarter 2024 Earnings: US$0.077 loss per share (vs US$0.13 loss in 2Q 2023)

Simply Wall St.

a year ago

Elevai Labs Second Quarter 2024 Earnings: US$0.077 loss per share (vs US$0.13 loss in 2Q 2023)

Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications

GlobeNewswire

a year ago

Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications

Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

GlobeNewswire

a year ago

Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line

GlobeNewswire

a year ago

Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line

Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024

GlobeNewswire

a year ago

Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024

Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

GlobeNewswire

a year ago

Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

Better AI Stock: Palantir vs. Snowflake

Motley Fool

a year ago

Better AI Stock: Palantir vs. Snowflake

Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?

Motley Fool

a year ago

Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?

BigBear.ai Stock: Buy, Sell, or Hold?

Motley Fool

a year ago

BigBear.ai Stock: Buy, Sell, or Hold?

Indonesia's first Olympic gymnast encourages others to 'dream higher'

AFP

a year ago

Indonesia's first Olympic gymnast encourages others to 'dream higher'

Where Will CrowdStrike Stock Be in 1 Year?

Motley Fool

a year ago

Where Will CrowdStrike Stock Be in 1 Year?

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

GuruFocus.com

a year ago

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

GuruFocus.com

a year ago

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)

Simply Wall St.

a year ago

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)

Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm

GlobeNewswire

a year ago

Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm

Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference

GlobeNewswire

a year ago

Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference

Elevai Labs Inc. Reports First Quarter 2024 Financial Results

GlobeNewswire

a year ago

Elevai Labs Inc. Reports First Quarter 2024 Financial Results

Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity

GlobeNewswire

a year ago

Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity

Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare

GlobeNewswire

a year ago

Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare

Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments

GlobeNewswire

a year ago

Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments

Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments

GlobeNewswire

a year ago

Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments

MT Newswires

a year ago

Elevai Labs Signs Exclusive Distribution Deal for Taiwan

ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months

GlobeNewswire

a year ago

ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months

Share on Social Networks: